We identified 6 candidate genes (TFRC, TNFSF14, LAMC1, PLK1, TYMS, and TSSK6) with strong evidence supporting their role in CRC pathogenesis and druggability. This evidence concerns the gene PLK1 and colorectal carcinoma.